Cargando…

Adipositas und Typ-2-Diabetes (Update 2023)

The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are...

Descripción completa

Detalles Bibliográficos
Autores principales: Clodi, Martin, Toplak, Hermann, Resl, Michael, Brix, Johanna, Leitner, Deborah Raphaela, Harreiter, Jürgen, Hoppichler, Friedrich, Wascher, Thomas C., Schindler, Karin, Ludvik, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133053/
https://www.ncbi.nlm.nih.gov/pubmed/37101029
http://dx.doi.org/10.1007/s00508-023-02184-6
_version_ 1785031512317493248
author Clodi, Martin
Toplak, Hermann
Resl, Michael
Brix, Johanna
Leitner, Deborah Raphaela
Harreiter, Jürgen
Hoppichler, Friedrich
Wascher, Thomas C.
Schindler, Karin
Ludvik, Bernhard
author_facet Clodi, Martin
Toplak, Hermann
Resl, Michael
Brix, Johanna
Leitner, Deborah Raphaela
Harreiter, Jürgen
Hoppichler, Friedrich
Wascher, Thomas C.
Schindler, Karin
Ludvik, Bernhard
author_sort Clodi, Martin
collection PubMed
description The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m(2) with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept.
format Online
Article
Text
id pubmed-10133053
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-101330532023-04-28 Adipositas und Typ-2-Diabetes (Update 2023) Clodi, Martin Toplak, Hermann Resl, Michael Brix, Johanna Leitner, Deborah Raphaela Harreiter, Jürgen Hoppichler, Friedrich Wascher, Thomas C. Schindler, Karin Ludvik, Bernhard Wien Klin Wochenschr Leitlinien Für Die Praxis The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m(2) with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept. Springer Vienna 2023-04-20 2023 /pmc/articles/PMC10133053/ /pubmed/37101029 http://dx.doi.org/10.1007/s00508-023-02184-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Leitlinien Für Die Praxis
Clodi, Martin
Toplak, Hermann
Resl, Michael
Brix, Johanna
Leitner, Deborah Raphaela
Harreiter, Jürgen
Hoppichler, Friedrich
Wascher, Thomas C.
Schindler, Karin
Ludvik, Bernhard
Adipositas und Typ-2-Diabetes (Update 2023)
title Adipositas und Typ-2-Diabetes (Update 2023)
title_full Adipositas und Typ-2-Diabetes (Update 2023)
title_fullStr Adipositas und Typ-2-Diabetes (Update 2023)
title_full_unstemmed Adipositas und Typ-2-Diabetes (Update 2023)
title_short Adipositas und Typ-2-Diabetes (Update 2023)
title_sort adipositas und typ-2-diabetes (update 2023)
topic Leitlinien Für Die Praxis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133053/
https://www.ncbi.nlm.nih.gov/pubmed/37101029
http://dx.doi.org/10.1007/s00508-023-02184-6
work_keys_str_mv AT clodimartin adipositasundtyp2diabetesupdate2023
AT toplakhermann adipositasundtyp2diabetesupdate2023
AT reslmichael adipositasundtyp2diabetesupdate2023
AT brixjohanna adipositasundtyp2diabetesupdate2023
AT leitnerdeborahraphaela adipositasundtyp2diabetesupdate2023
AT harreiterjurgen adipositasundtyp2diabetesupdate2023
AT hoppichlerfriedrich adipositasundtyp2diabetesupdate2023
AT wascherthomasc adipositasundtyp2diabetesupdate2023
AT schindlerkarin adipositasundtyp2diabetesupdate2023
AT ludvikbernhard adipositasundtyp2diabetesupdate2023